Physician profile
Kevin V Ware
NPI 1609817980
$1,109,410.67
in general payments reported to CMS, 2019-2025
27 companies · $283K in 2025
The $283K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96K · 2020: $41K · 2021: $62K · 2022: $177K · 2023: $200K · 2024: $250K · 2025: $283K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $603K · Travel and Lodging: $91K · Food and Beverage: $21K · Consulting Fee: $18K · Education: $7.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $603,185.00 |
| Travel and Lodging | $91,457.96 |
| Food and Beverage | $20,774.78 |
| Consulting Fee | $17,690.00 |
| Education | $7.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $612,966.85 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $416,598.87 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $40,250.20 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $23,040.31 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Vanda Pharmaceuticals INC. | $8,056.28 | 2019-2025 | Fanapt, Hetlioz |
| Gilead Sciences, INC. | $2,070.41 | 2023-2025 | Epclusa |
| Takeda Pharmaceuticals U.S.A., INC. | $1,951.24 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $1,654.16 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Axsome Therapeutics, INC. | $579.59 | 2022-2025 | Auvelity |
| Bausch Health US, LLC | $464.53 | 2019-2023 | Aplenzin, Wellbutrin |
| E.R. Squibb & Sons, L.L.C. | $227.61 | 2025 | Cobenfy |
| Indivior INC. | $218.99 | 2020-2024 | Sublocade, Perseris |
| Otsuka America Pharmaceutical, INC. | $188.65 | 2019-2024 | Rexulti, Nuedexta |
| Idorsia Pharmaceuticals US INC | $181.00 | 2022-2025 | Quviviq, Quviviq |
| Uswm, LLC | $147.05 | 2022-2023 | Zimhi, Lucemyra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $127.89 | 2024-2025 | Brixadi |
| Validus Pharmaceuticals LLC | $126.37 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $124.03 | 2019 | |
| Abbvie INC. | $113.35 | 2021-2024 | Vraylar |
| Hikma Pharmaceuticals USA | $75.64 | 2022 | |
| Janssen Scientific Affairs, LLC | $66.09 | 2020 | |
| Noven Therapeutics, LLC | $52.35 | 2021-2022 | |
| Orexo US, INC. | $45.13 | 2019-2024 | Zubsolv |
| Neurocrine Biosciences, INC. | $27.47 | 2024 | Ingrezza |
| Noven Pharmaceuticals, INC. | $21.77 | 2021 | |
| Avanir Pharmaceuticals, INC. | $20.20 | 2019 | |
| Lundbeck LLC | $14.64 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Ware listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.